Use of memantine for the treatment of dementia

Expert Review of Neurotherapeutics

Volumn 11, Issue 10, 2011, Pages 1359-1370

  Lo, Daphne ^a,b   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimers disease; dementia; memantine; NMDA receptor antagonist

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; KETAMINE; MEMANTINE; METFORMIN; PLACEBO; RIVASTIGMINE;

ACCIDENTAL INJURY; AGITATION; ALZHEIMER DISEASE; AMPUTATION; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CATATONIC SCHIZOPHRENIA; CONFUSION; CONSTIPATION; DIFFUSE LEWY BODY DISEASE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FRONTOTEMPORAL DEMENTIA; HEADACHE; HUMAN; MILD COGNITIVE IMPAIRMENT; MONOTHERAPY; NERVE CELL DEGENERATION; NEUROPATHIC PAIN; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHANTOM PAIN; SIDE EFFECT; SOMNOLENCE; TRAUMATIC BRAIN INJURY; URINARY TRACT INFECTION;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEMENTIA; DOPAMINE AGENTS; HUMANS; INDANS; MEMANTINE; NEURODEGENERATIVE DISEASES; PIPERIDINES;

EID: 80053496865     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.132     Document Type: Article

References (43)

1. Querfurth HW, LaFerla FM. Mechanisms of disease: Alzheimers disease. N. Engl. J. Med. 362, 329-344 (2010)
2. Hermann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Expert Opin. Pharmacother. 12(5), 787-800 (2011)
3. Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimers disease and other dementias. Clin. Interv. Aging 4, 367-377 (2009)
4. Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr. Neuropharmacol. 6, 55-78 (2008) (Pubitemid 351513473)
5. Kavirajan H. Memantine: a comprehensive review of safety and efficacy. Expert Opin. Drug Saf. 8(1), 89-109 (2009)
6. Jones RW, Bayer A, Inglis F, Barker A, Phul R. Safety and tolerability of once-daily versus twice-daily memantine: a randomized, double-blind study in moderate to severe Alzheimers disease. Int. J. Geriatr. Psychiatry 22, 258-262 (2007) (Pubitemid 46431716)
7. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-BEST Study (Benefit and Efficacy in Severely Demented Patients During Treatment with Memantine). Int. J. Geriatr. Psychiatry 14, 135-146 (1999) (Pubitemid 29110331)
8. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimers disease. N. Engl. J. Med. 348, 1333-1341 (2003)
9. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch. Neurol. 63, 49-54 (2006) (Pubitemid 43063861)
10. van Dyck CH, Tariot PN, Meyers B, Resnick EM. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis. Assoc. Discord. 21, 136-143 (2007) (Pubitemid 46878975)
11. Livingston G, Katona C. The place of memantine in the treatment of Alzheimers disease: a number needed to treat analysis. Int. J. Geriatr. Psychiatry 19, 919-925 (2004)
12. Rasmusson DD, Banerjee PK, Semba K. Synergistic effects of acetylcholinesterase (AChE) inhibition and NMDA receptor modulation of acetylcholine levels. Biol. Psychiatry 59(8 Suppl. 1), 2055-2056 (2006)
13. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil a randomized controlled trial. JAMA 291, 317-324 (2004) (Pubitemid 38101604)
14. Choi SH, Park KW, Na DL et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimers disease: a multi-center, randomized, open-label, parallel study group. Curr. Med. Res. Opin. 27(7), 1375-1383 (2011)
15. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere J-J, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimers disease who failed to benefit from previous cholinesterase inhibitor treatment. Int. J. Clin. Pract. 60(1), 110-118 (2006) (Pubitemid 43732587)
16. Atri A, Shaughness LW, Locascio JJ, Growden JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Discord. 22, 209-221 (2008)
17. Lopez OL, Becker JT, Wahed AS et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 80(6), 600-607 (2009)
18. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res. Ther. 1(2), 7 (2009)
19. Maidment IA, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann. Pharmacother. 42, 32-38 (2008)
20. Peskind ER, Potkin SG, Pomara N et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am. J Geriatr. Psychiatry 12, 704-715 (2006) (Pubitemid 44196270)
21. Pomara N, Ott BR, Peskind E, Resnick EM. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis. Assoc. Discor. 21(1), 60-64 (2007)
22. Bakchine S, Loft H. Memantine Treatment in patients with mild to moderate Alzheimers disease: results of a randomised, double-blind, placebo-controlled 6-month study. J. Alzheimers Dis. 12, 97-107 (2008) (Pubitemid 351365621)
23. McShane R, Sastre AA, Minkaran N. Memantine for dementia (review). Cochrane Database Syst Rev. 1, 1469-493X (2009)
24. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimers disease already receiving a cholinesterase inhibitor: a randomized double-blind, placebo-controlled trial. Curr. Alzheimers Res. 5, 83-89 (2008) (Pubitemid 351536358)
25. Schneider LS, Dagerman KS, Higgins JPT, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch. Neurol. 68(8), 991-998 (2011)
26. Petersen RC. Mild cognitive impairment. N. Engl. J. Med. 364, 2227-2234 (2011)
27. Schneider LS, Insel PS, Weiner MW. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimers disease neuroimaging initiative. Arch. Neurol. 68(1), 58-66 (2011)
28. Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinsons disease dementia or dementia with Lewy bodies a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8(7), 613-618 (2009)
29. Litvinenko IV, Odinak MM, Mogilnaya VI, Perstnev SV. Use of Memantine (akatinol) for the correction of cognitive impairments in Parkinsons disease complicated by dementia. Neurosci. Behav. Physiology 40(2), 149-155 (2010)
30. Emre M, Tsolaki M, Bonuccelli U et al. Memantine for patients with Parkinsons disease dementia or dementia with Lewy bodies: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 9, 969-977 (2010)
31. Hu B, Ross L, Neuhaus J et al. Off-label medication use in frontotemporal dementia. Am. J Alzheimers. Dis. Other. Demen. 5(2), 128-133 (2010)
32. Diehl-Schmid J, Forstl H, Perneczky R, Pohl C, Kurz A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int. J Geriatr. Psychiatry 23, 754-759 (2008)
33. Boxer AL, Lipton AM, Womack K et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis. Assoc. Discord. 23, 211-217 (2009)
34. Collins SC, Sigtermans MJ, Dahan A, Zuurmond WW, Perez RS. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med. 11, 1726-1742 (2010)
35. Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1362-1374 (2008) (Pubitemid 352033662)
36. Zarate CA, Singh JB, Quiroz JA et al. A double-blind placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry 163(1), 153-155 (2006) (Pubitemid 43050119)
37. Rao VL, Dogan A, Todd KG, Bowen KK, Dempsey RJ. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res. 911(1), 96-100 (2001) (Pubitemid 32728243)
38. Chen XH, Johnson VE, Uryu K, Trojanowski JQ, Smit DH. A lack of amyloid b plaques despite persistent accumulation of amyloid b in axons of long-term survivors of traumatic brain injury. Brain Pathol. 19(2), 214-233 (2009)
39. Kim YW, Shin J, An Y. Changes in cerebral glucose metabolism in patients with posttraumatic cognitive impairment after memantine therapy: a preliminary study. Ann. Nucl. Med. 24, 363-369 (2010)
40. Bassil N, Thaipissuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimers disease. Expert Opin. Pharmacotherap. 11, 1765-1771 (2010)
41. Department of Health and Human Services www.accessdata.fda.gov/ drugsatfda-docs/appletter/2006/020690s026,021720s003L TR.pdf
42. Namenda www.frx.com/pi/Namenda-pi.pdf
43. FDA www.accessdata.fda.gov/drugsatfda-docs/label/2010/022525s000lbl.pdf